Quantcast
Thursday, November 21, 2024

Pfizer Board Member Reveals New COVID ‘Delta Plus’ Variant; More Vaccines to Come?

'We need urgent research to figure out if this delta plus is more transmissible, has partial immune evasion?'

Scott Gottlieb, a Pfizer board member and former FDA commissioner, excitedly tweeted Sunday about the emergence of the new “AY.4” coronavirus variant, which will require even more vaccines.

According to Gottlieb, COVID surges have started again.

“UK reported its biggest one-day Covid case increase in 3 months just as the new delta variant AY.4 with the S:Y145H mutation in the spike reaches 8% of UK sequenced cases,” he wrote on Twitter.

He called the new variant the foreboding “delta plus,” suggesting that it may require even more vaccines, presumably made by Pfizer.

“We need urgent research to figure out if this delta plus is more transmissible, has partial immune evasion?”

Continuing his tweet thread, Gottlieb advocated for more intrusive regulation in order to study the virus and its spread.

“The variant has been in the UK since about July, but it has been slowly increasing in prevalence,” he said.

“There’s no clear indication that it’s considerably more transmissible, but we should work to more quickly characterize these and other new variants,” he continued. “We have the tools.”

Gottlieb then pushed for the creation of a “robust” global system to “identify, characterize new variants” in order to ensure “a coordinated, global priority for Covid.”

Of course, the ruling class has long dreamed of universal vaccination, and big pharmaceutical companies have taken no issue with that.

Yet universal vaccination would require a great deal of fearmongering, which our rulers seem well aware of.

Coronavirus czar Anthony Fauci several years ago urged universal vaccination, claiming that he must simply ignore political procedures and popular conceptions about disease and “address the problem in a disruptive way and in an iterative way’—because you do need both.”

Copyright 2024. No part of this site may be reproduced in whole or in part in any manner other than RSS without the permission of the copyright owner. Distribution via RSS is subject to our RSS Terms of Service and is strictly enforced. To inquire about licensing our content, use the contact form at https://headlineusa.com/advertising.
- Advertisement -

TRENDING NOW

TRENDING NOW